Breast Cancer - Moose and Doc

A breast cancer explanations website

 

By Dr. Halls

References for Breast Cancer Survival Rates: What you need to know

 

  • American Cancer Society: Cancer Facts and Figures 2011. Atlanta, Ga: American Cancer Society,(2011).
  • Anders CK,Johnson R, Litton J, Phillips M, Bleyere A. (2009) Breast Cancer Before Age 40 Years Semin Oncol. 2009 Jun; 36(3): 237–249. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894028/
  • Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res.(2004) ;6(3):R149-56. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400666/
  • Brandt J, Garne JP, Tengrup I, Manjer J (2015) Age at diagnosis in relation to survival following breast cancer: a cohort study. World Journal of Surgical Oncology201513:33 http://wjso.biomedcentral.com/articles/10.1186/s12957-014-0429-x
  • Bloom HJ, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J. (July 1970)25;3(5716):181-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1701103/
  • Cao AY, He M, Huang L, Shao ZM, Di GH (2013) Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. https://wjso.biomedcentral.com/articles/10.1186/1477-7819-11-91
  • Cook DL, Weaver DL. Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol 1995 Jul;104(1):17-22 https://www.ncbi.nlm.nih.gov/pubmed/7611175
  • Cornford EJ, Wilson AR, Athanassiou E, et al. Mammographic features of invasive lobular and invasive ductal carcinoma of the breast (a comparative analysis). Br J Radiol. (1995);68:450–453 https://www.ncbi.nlm.nih.gov/pubmed/7788227
  • Dumitru A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache M, et al (2015) Mucinous Breast Cancer: a Review Study of 5 Year Experience from a Hospital-Based Series of Cases. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496759/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496759/
  • Grube BJ, Hansen NM, Ye X, et al. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg. 2002;184:372–376. https://www.ncbi.nlm.nih.gov/pubmed/12383906
  • Howlader N, Noone AM, Krapcho M, et al (eds) SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD,. http://seer.cancer.gov/csr/1975_2010/
  • Jain S, Fisher C, Smith P, et al. Patterns of metastatic breast cancer in relation to histologic type. Eur J Cancer. (1993) ;29A:2155–2157 https://www.sciencedirect.com/science/article/pii/095980499390053I
  • Mansfield CM, Komarnicky LT, Schwartz GF, et al. Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer. (1995);75:2328–2336 https://www.ncbi.nlm.nih.gov/pubmed/7712444
  • Memis A, Ozdemir N, Parildar M, Ustun EE, Erhan Y. Mucinous (colloid) breast cancer: mammographic and US features with histologic correlation. Eur J Radiol. (July 2000) l;35(1):39-43. https://www.ncbi.nlm.nih.gov/pubmed/10930764
  • Narod SA, Iqbal J, Giannakeas V, et al.Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ (2015) JAMA Oncol. 2015;1(7):888-896. http://jamanetwork.com/journals/jamaoncology/article-abstract/2427491
  • Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist. (1998);3(4):237-252. https://www.ncbi.nlm.nih.gov/pubmed/9831867
  • Shenkier T, Weir L, Levine M et al. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004); 170: 983–994.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359433/
  • Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg.(Aug. 2005) 242(2):281-9.   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1357735/
  • Soo Youn Bae, Min-Young Choi, Dong Hui Cho, Jeong Eon Lee, Seok Jin Nam, and Jung-Hyun Yang Mucinous Carcinoma of the Breast in Comparison with Invasive Ductal Carcinoma: Clinicopathologic Characteristics and Prognosis.
    J Breast Cancer. 2011 Dec;14(4):308-313. English. https://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2011.14.4.308
  • Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.  https://www.ncbi.nlm.nih.gov/pubmed/2569032
  • Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, et al. (2015) Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.. https://www.ncbi.nlm.nih.gov/pubmed/23648437
  • Wasif N, Maggard MA, KoArmando CY, Giuliano E Invasive Lobular vs. Ductal Breast Cancer: A Stage-Matched Comparison of Outcomes.https://link.springer.com/article/10.1245/s10434-010-0953-z
  • Winchester DJ, Sahin AA, Tucker SL, Singletary SE. Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg. (Mar. 1996) 223(3):342-7.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1235123/
  • Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat (2008); 109: 417–426.  https://www.ncbi.nlm.nih.gov/pubmed/17653852
  • World Cancer Report. International Agency for Research on Cancer. (2008).
  • Zurawska U, Baribeau DA, Giilck S, Victor C, Gandhi S, et al. (2013)Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients Curr Oncol. 2013 Dec; 20(6): e539–e545. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851350/